IgY Industries and Markets

Vieira-Pires, Ricardo S.; Ahn, Hyeong Chul; Bok, Marina; Caulfield, Catherine D.; Chacana, Pablo; Elahi, Fazle; Larsson, Anders; Leiva, Carlos Leónidas; Moran, Leonard M.; Morgan, Patricia M.; Parreño, Viviana; Vega, Celina G.; Wigdorovitz, Andrés

doi:10.1007/978-3-030-72688-1_17

Cited by 6 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A major limitation for IgY-based technology is the lack of standardization in animal experiments as well as in purification method . Notably, built upon accumulated studies on IgY technology, the manuals for best practices in IgY technology are indeed available, and European Centre for the Validation of Alternative Method (ECVAM) has recognized IgY technology as an international standardized technology. , However, to develop an effective and sustainable IgY-based passive immune intervention with standardized IgY technology, several significant challenges associated with IgY, such as in vivo stability, purification, heterologous immunogenicity, and repertoire diversity, need to be recognized and addressed. In particular, assessment of in vivo stability and bioavailability of IgY is critically important in both human trials and animal studies to increase the relevance of the observed phenotypes to the functionality of the administered egg yolk IgY.…”

Section: Discussionmentioning

confidence: 99%

Egg Yolk Antibody for Passive Immunization: Status, Challenges, and Prospects

Wang

Zhong

Lin

2023

J. Agric. Food Chem.

View full text Add to dashboard Cite

The immunoglobulin Y (IgY) derived from hyperimmune egg yolk is a promising passive immune agent to combat microbial infections in humans and livestock. Numerous studies have been performed to develop specific egg yolk IgY for pathogen control, but with limited success. To date, the efficacy of commercial IgY products, which are all delivered through an oral route, has not been approved or endorsed by any regulatory authorities. Several challenging issues of the IgY-based passive immunization, which were not fully recognized and holistically discussed in previous publications, have impeded the development of effective egg yolk IgY products for humans and animals. This review summarizes major challenges of this technology, including in vivo stability, purification, heterologous immunogenicity, and repertoire diversity of egg yolk IgY. To tackle these challenges, potential solutions, such as encapsulation technologies to stabilize IgY, are discussed. Exploration of this technology to combat the COVID-19 pandemic is also updated in this review.

show abstract

Section: Discussionmentioning

confidence: 99%

Egg Yolk Antibody for Passive Immunization: Status, Challenges, and Prospects

Wang

Zhong

Lin

2023

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“…To meet the diversified application needs, increased IgY products have been developed and distributed in the markets, in the form of new drugs, food, or feed additives in R&D pipeline, including clinical studies for anti-SARS-CoV-2 virus ( Kreuzberger et al, 2021 ; Vieira-Pires et al, 2021 ). However, the development of IgY technology still faces some technical barriers to be solved.…”

Section: Discussionmentioning

confidence: 99%

“…The unique advantages of IgY antibodies has led to the establishment of several companies, mainly focusing on immunoassay and oral therapy applications ( Vieira-Pires et al, 2021 ). However, different application scenarios impose distinct quality requirements on IgY products.…”

Section: Discussionmentioning

confidence: 99%

Proteomic investigation and understanding on IgY purification and product development

Zhang

Chelliappan

2023

Poultry Science

View full text Add to dashboard Cite

“…On the other hand, it is known that the IgY molecule possess a structure similarity with the human IgG, the difference being that IgY has four constant regions at the heavy chains by comparison with IgG. This similarity could shape the basis for designing anti-IgY-based therapeutical approaches in different pathological conditions, both for veterinary and human applications [16,17].…”

Section: Mechanism(s) Of Igy Action In the Gastrointestinal Tractmentioning

confidence: 99%

Immune Portrayal of a New Therapy Targeting Microbiota in an Animal Model of Psoriasis

Surcel,

Constantin,

Munteanu

et al. 2023

JPM

View full text Add to dashboard Cite

Background: Despite all the available treatments, psoriasis remains incurable; therefore, finding personalized therapies is a continuous challenge. Psoriasis is linked to a gut microbiota imbalance, highlighting the importance of the gut–skin axis and its inflammatory mediators. Restoring this imbalance can open new perspectives in psoriasis therapy. We investigated the effect of purified IgY raised against pathological human bacteria antibiotic-resistant in induced murine psoriatic dermatitis (PSO). Methods: To evaluate the immune portrayal in an imiquimod experimental model, before and after IgY treatment, xMAP array and flow cytometry were used. Results: There were significant changes in IL-1α,β, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17a, IFN-γ, TNF-α, IP-10/CXCL10, MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, MIG/CXCL9, and KC/CXCL1 serum levels. T (CD3ε+), B (CD19+) and NK (NK1.1+) cells were also quantified. In our model, TNF-α, IL-6, and IL-1β cytokines and CXCL1 chemokine have extremely high circulatory levels in the PSO group. Upon experimental therapy, the cytokine serum values were not different between IgY-treated groups and spontaneously remitted PSO. Conclusions: Using the murine model of psoriatic dermatitis, we show that the orally purified IgY treatment can lead to an improvement in skin lesion healing along with the normalization of cellular and humoral immune parameters.

show abstract

IgY Industries and Markets

Cited by 6 publications

References 27 publications

Egg Yolk Antibody for Passive Immunization: Status, Challenges, and Prospects

Egg Yolk Antibody for Passive Immunization: Status, Challenges, and Prospects

Proteomic investigation and understanding on IgY purification and product development

Immune Portrayal of a New Therapy Targeting Microbiota in an Animal Model of Psoriasis

Contact Info

Product

Resources

About